NRBO - NeuroBo Pharmaceuticals GAAP EPS of -$5.43

2023-03-30 17:20:22 ET

• NeuroBo Pharmaceuticals press release ( NASDAQ: NRBO ): FY GAAP EPS of -$5.43.
• Cash and Cash Equivalents were $33.4 million as of December 31, 2022, compared with $16.4 million as of December 31, 2021.
• Research and Development (R&D) Expenses were $2.8 million for the year ended December 31, 2022 as compared to $6.5 million for the year ended December 31, 2021.
• General and Administrative Expenses were $8.6 million for the year ended December 31, 2022, compared to $8.7 million for the year ended December 31, 2021.
• Net Loss for the year ended December 31, 2022 was $14.0 million, or $ 5.43 per basic and diluted share,

For further details see: